This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bardi, G. Articles by Heim, S. Search for Related Content PubMed PubMed Citation Articles by Bardi, G. Articles by Heim, S.

Tumor Karyotype Predicts Clinical Outcome in Colorectal Cancer Patients

From the Department of Genetics, "G. Papanikolaou" Research Center, Saint Savas Oncological Hospital, Athens, Greece; Department of Pathology, Odense University Hospital, Odense, Denmark; Department of Clinical Genetics, Lund University Hospital, Lund, Sweden; Department of Cancer Genetics, the Norwegian Radium Hospital, Oslo, Norway

Address reprint requests to Georgia Bardi, PhD, Department of Genetics, "G. Papanikolaou" Research Center, Saint Savas Oncological Hospital of Athens, 171 Alexandras Ave, Athens 115 22, Greece; e-mail: gbardi{at}hotmail.com

PURPOSE: To investigate the prognostic value of the overall karyotypic features and specific chromosome aberrations in colorectal cancer (CRC).

PATIENTS AND METHODS: Cytogenetic features of 150 primary CRCs investigated at the time of surgery were correlated with patient survival by univariate and multivariate analyses, using classical clinicopathologic parameters as covariates.

RESULTS: In univariate analysis, in addition to tumor grade and clinical stage, structural aberrations as well as rearrangements of chromosomes 8 and 16 were significantly correlated with shorter overall survival. Karyotypic complexity, rearrangements of chromosomes 8 and 16, and loss of chromosome 4 were significantly correlated with shorter disease-free survival. In multivariate analysis, in addition to tumor grade, the type of chromosome aberrations (structural or numerical), ploidy, and loss of chromosome 18 came across as independent prognostic factors in the group of all patients. In the subset of patients with stage I and II carcinomas, none of the clinicopathologic variables could independently predict patient survival, whereas the presence of structural chromosomal aberrations was the only independent predictor of poor prognosis. In the subset of patients with stage III carcinomas, the presence of structural changes of chromosome 8 was a stronger independent predictor of prognosis than was tumor grade.

CONCLUSION: Cytogenetic tumor features are valuable predictors of prognosis in CRC patients. The tumor karyotype should therefore be taken into account in the clinical management of patients with this disease, especially for patients having cancers of the early or intermediate stages I, II, and III.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				E. H. Lips, R. van Eijk, E. J.R. de Graaf, P. G. Doornebosch, N. F.C.C. de Miranda, J. Oosting, T. Karsten, P. H.C. Eilers, R. A.E.M. Tollenaar, T. van Wezel, et al. Progression and Tumor Heterogeneity Analysis in Early Rectal Cancer Clin. Cancer Res., February 1, 2008; 14(3): 772 - 781. [Abstract] [Full Text] [PDF]

				A. V. Roschke, S. Lababidi, G. Tonon, K. S. Gehlhaus, K. Bussey, J. N. Weinstein, and I. R. Kirsch Karyotypic "state" as a potential determinant for anticancer drug discovery PNAS, February 22, 2005; 102(8): 2964 - 2969. [Abstract] [Full Text] [PDF]